Evidence map›Paper›PMID 29143869›Full record

ArticlePsychopharmacology2018

Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication.

E Haijen, M Farre, R de la Torre, A Pastor, E Olesti, N Pizarro, J G Ramaekers, K P C Kuypers

Open access · hybridAbstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

E HaijenDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.
M FarreIntegrative Pharmacology & Neurosciences Systems Research Group, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
R de la TorreIntegrative Pharmacology & Neurosciences Systems Research Group, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
A PastorIntegrative Pharmacology & Neurosciences Systems Research Group, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
E OlestiIntegrative Pharmacology & Neurosciences Systems Research Group, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
N PizarroIntegrative Pharmacology & Neurosciences Systems Research Group, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
J G RamaekersDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.
K P C KuypersDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands. k.kuypers@maastrichtuniversity.nl.
Hospital del Mar Research Institute · ESMaastricht University · NLPompeu Fabra University · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ES

Funding

Generalitat de Catalunya 2014SGR 680Nederlandse Organisatie voor Wetenschappelijk Onderzoek 400-07-2013
6 · The paper itself

Abstract

backgroundPreclinical data have suggested involvement of the endocannabinoid (eCB) system in MDMA-induced memory impairment. Clinical research has shown that blockade of the 5-HT

methodsTwenty healthy recreational polydrug users entered a double-blind placebo-controlled within-subject study. Participants received a pre-treatment (ketanserin 40 mg, placebo) followed 30 min later by a treatment (MDMA 75 mg, placebo). Verbal memory was tested by means of a 30-word learning test. Endocannabinoid concentrations (anandamide (2-AG); N-arachidonylethanolamine (AEA)) were assessed in blood at baseline, before (90 min post-treatment) and after cognitive tests (150 min post-treatment).

resultsFindings showed that MDMA impaired memory 90 min post-treatment in the word learning task. This effect was a replication of previous studies using the same dose of MDMA (75 mg) and the same learning paradigm. Contrary to our hypothesis, MDMA did not affect eCB concentrations, nor did ketanserin block MDMA-induced memory impairment. Ketanserin caused an increase in AEA concentrations, 180 min after administration.

conclusionCurrent findings suggest that peripherally measured endocannabinoids are not associated with the verbal memory deficit during MDMA intoxication. TRIAL REGISTRATION NUMBER: NTR3691.

Indexed as

AdultArachidonic AcidsDouble-Blind MethodEndocannabinoidsFemaleHumansKetanserinMaleMemory DisordersN-Methyl-3,4-methylenedioxyamphetaminePolyunsaturated AlkamidesSerotonin 5-HT2 Receptor AntagonistsSerotonin AgentsVerbal LearningYoung AdultanandamideArachidonic AcidsEndocannabinoidsKetanserinN-Methyl-3,4-methylenedioxyamphetaminePolyunsaturated AlkamidesSerotonin 5-HT2 Receptor AntagonistsSerotonin Agents2-AG5-HT2 receptorAEAEndocannabinoidsKetanserinMDMAVerbal memory

Identifiers

PMID29143869
PMCPMC5847074
OpenAlexW2769063767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.